Use of pharmacodynamic/response biomarkers for therapeutic biologics regulatory submissions

References

• 1. Amur S, Frueh FW, Lesko LJ, Huang SM. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark. Med., 2(3), 305–311 (2008).
  CASGoogle Scholar
• 2. Zineh I, Huang SM. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark. Med., 5(6), 705–713 (2011).
  CASGoogle Scholar
• 3. Schuck RN, Pacanowski M, Woodcock J, Zineh I. Regulatory policy for the development of targeted therapies for low-frequency molecular subtypes of disease. Nat. Rev. Drug Discov., 17(2), 79–80 (2018).
  Medline CASGoogle Scholar
• 4. Popa ML, Albulescu R, Neagu M, Hinescu ME, Tanase C. Multiplex assay for multiomics advances in personalized-precision medicine. J. Immunoassay Immunochem., 40(1), 3–25 (2019).
  Medline CASGoogle Scholar
• 5. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource (2016). www.ncbi.nlm.nih.gov/pubmed/27010052
  Google Scholar
• 6. Amur S, Lavange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin. Pharmacol. Ther., 98(1), 34–46 (2015).
  Medline CASGoogle Scholar
• 7. Goodsaid FM, Amur S, Aubrecht J et al. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat. Rev. Drug Discov., 9(6), 435–445 (2010).
  Medline CASGoogle Scholar
• 8. Hayes DF. Biomarker validation and testing. Mol. Oncol., 9(5), 960–966 (2015).
  MedlineGoogle Scholar
• 9. US FDA. FDA's guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product (2016). www.fda.gov/media/88622/download
  Google Scholar
• 10. Sheiner LB. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther., 61(3), 275–291 (1997).
  Medline CASGoogle Scholar
• 11. Schuck E, Bohnert T, Chakravarty A et al. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape. AAPS J., 17(2), 462–473 (2015).
  Medline CASGoogle Scholar
• 12. Heatherington AC, Kasichayanula S, Venkatakrishnan K. How well are we applying quantitative methods to reverse translation to inform early clinical development? Clin. Pharmacol. Ther., 103(2), 174–176 (2018).
  MedlineGoogle Scholar
• 13. US FDA. Table of surrogate endpoints that were the basis of drug approval or licensure (2019). www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
  Google Scholar
• 14. US FDA. Listing of FDA's biosimilarity guidances (2019). www.fda.gov/vaccines-blood-biologics/general-biologics-guidances/biosimilars-guidances
  Google Scholar
• 15. Yao HM, Ottery FD, Borema T et al. PF-06881893 (Nivestym), a filgrastim biosimilar, versus US-licensed filgrastim reference product (US-Neupogen^®): pharmacokinetics, pharmacodynamics, immunogenicity, and safety of single or multiple subcutaneous doses in healthy volunteers. BioDrugs, 33(2), 207–220 (2019).
  Medline CASGoogle Scholar
• 16. Waller CF, Tiessen RG, Lawrence TE et al. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J. Cancer Res. Clin. Oncol., 144(6), 1087–1095 (2018).
  Medline CASGoogle Scholar
• 17. Stalker D, Reid S, Ramaiya A, Wisemandle WA, Martin NE. Pharmacokinetic and pharmacodynamic equivalence of epoetin hospira and epogen after single subcutaneous doses to healthy male subjects. Clin. Ther., 38(8), 1778–1788 (2016).
  Medline CASGoogle Scholar
• 18. Stalker D, Ramaiya A, Kumbhat S, Zhang J, Reid S, Martin N. Pharmacodynamic and pharmacokinetic equivalences of epoetin hospira and Epogen^® after multiple subcutaneous doses to healthy male subjects. Clin. Ther., 38(5), 1090–1101 (2016).
  Medline CASGoogle Scholar
• 19. Zhu P, Sy SKB, Skerjanec A. Application of pharmacometric analysis in the design of clinical pharmacology studies for biosimilar development. AAPS J., 20(2), 40 (2018).
  MedlineGoogle Scholar
• 20. Wang YC, Wang Y, Schrieber SJ et al. Role of modeling and simulation in the development of novel and biosimilar therapeutic proteins. J. Pharm. Sci., 108(1), 73–77 (2019).
  Medline CASGoogle Scholar